12
Cryptococcal Capsule and IRIS Darin L Wiesner

Cryptococcal Capsule and IRIS

  • Upload
    khoi

  • View
    49

  • Download
    0

Embed Size (px)

DESCRIPTION

Cryptococcal Capsule and IRIS. Darin L Wiesner. Healthy Response To Cryptococcus. Normal. Adapted from Wiesner and Boulware , Curr Fungal Infect Rep 2011. Healthy Response To Cryptococcus. Normal. Adapted from Wiesner and Boulware , Curr Fungal Infect Rep 2011. - PowerPoint PPT Presentation

Citation preview

Page 1: Cryptococcal  Capsule and IRIS

Cryptococcal Capsule and IRIS

Darin L Wiesner

Page 2: Cryptococcal  Capsule and IRIS

Healthy Response To Cryptococcus

Normal

Adapted from Wiesner and Boulware, Curr Fungal Infect Rep 2011

Page 3: Cryptococcal  Capsule and IRIS

Healthy Response To Cryptococcus

Normal

Adapted from Wiesner and Boulware, Curr Fungal Infect Rep 2011

Page 4: Cryptococcal  Capsule and IRIS

Healthy Response To Cryptococcus

Normal

Adapted from Wiesner and Boulware, Curr Fungal Infect Rep 2011

Page 5: Cryptococcal  Capsule and IRIS

Theory of CM-IRIS Pathogenesis

Adapted from Wiesner and Boulware, Curr Fungal Infect Rep 2011

Pathologic

Page 6: Cryptococcal  Capsule and IRIS

Hypothesis:

• CM Patients that mount an ineffective ex vivo cytokine response to cryptococcal capsular antigen are at increased risk for death or IRIS.

Page 7: Cryptococcal  Capsule and IRIS

45%

20%

35%

Patient Characteristics

CM Only

CM-IRIS

Death

Ineffective Response

Normal Response

Page 8: Cryptococcal  Capsule and IRIS

45%

20%

35%

Patient Characteristics

CM Only

CM-IRIS

Death

Ineffective Response

Normal Response

Page 9: Cryptococcal  Capsule and IRIS

Cytokine Response to Capsular Antigen

Equivalent

Significantly Elevated

Cytokine Response Relativeto Negative Control:

Page 10: Cryptococcal  Capsule and IRIS

Multivariate Model of IRIS/Death Risk

Page 11: Cryptococcal  Capsule and IRIS

Theory of CM-IRIS Pathogenesis

Adapted from Wiesner and Boulware, Curr Fungal Infect Rep 2011

Pathologic

Page 12: Cryptococcal  Capsule and IRIS

Acknowledgements• Mentorship:

– David Boulware, U of MN– Paul Bohjanen, U of MN– Kirsten Nielsen, U of MN

• Reagents and/or Discussion:– Stu Levitz, U of MA– Nielsen Lab, U of MN– Mellissa Rolfes, U of MN

• Clinic:– David Meya, IDI - Kampala– Andrew Kumbugu, IDI – Kampala

• Laboratory:– Henry Kajambula, Makerere U– Andrew Akampurira, Makerere U– Beatrice Achan, Makerere U